|Bid||23.59 x 1400|
|Ask||28.13 x 1300|
|Day's Range||23.58 - 24.13|
|52 Week Range||23.58 - 37.95|
|Beta (3Y Monthly)||0.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.00|
Natus Medical (BABY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PLEASANTON, Calif., April 11, 2019 -- Natus Medical Incorporated (NASDAQ: BABY), a leading provider of medical devices and services, today announced that the Company will.
Natus Medical Inc NASDAQ/NGS:BABYView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for BABY with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. ETFs that hold BABY had net inflows of $1.48 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
PLEASANTON, Calif., April 08, 2019 -- Natus Medical Incorporated (NASDAQ: BABY), a leading provider of medical devices and services, today announced that the Company will.
Per Natus Medical (BABY), this deal is strategically aligned with its business as besides concentrating on its core products, this sell-off will lead to planned investment in the high-growth markets.
Natus Medical Incorporated (BABY) (the “Company” or “Natus”), a leading provider of medical devices and services, today announced that it has signed a definitive agreement to sell its wholly-owned subsidiary, Medix Medical Devices, SRL (“Medix”), in an employee led buyout. As part of this divestiture, Natus will sell the Medix line of products, including incubators, warmers and other Medix products. Under its new ownership, Medix will continue to distribute Medix products as well as the previously distributed line of Natus products and other third party products in Argentina and Venezuela. Medix will also provide ongoing customer service, sales and customer support, and warranty and repair services for the Medix line of products.
NEW YORK, March 29, 2019 -- Bragar Eagel & Squire, P.C. is investigating potential claims against Natus Medical Incorporated (NASDAQ: BABY). Our investigation concerns.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Natus Medical Incorporated .
Most biotech drugs focus on clearing plaques from brain cells, but restoring patients' sleep quality is also proving to be necessary.
Natus Medical Inc provides newborn care, neurology healthcare products and services used for screening, diagnosis, detection, treatment, monitoring and tracking of medical ailments in newborn care, epilepsy, and balance and mobility disorders. Natus Medical Inc had annual average EBITDA growth of 10.50% over the past ten years. Warning! GuruFocus has detected 3 Warning Signs with BABY.
PLEASANTON, Calif., March 01, 2019 -- Natus Medical Incorporated (NASDAQ: BABY) today announced its upcoming conference schedule for March: Raymond James 40th Annual.
NEW YORK, Feb. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
tumbled 12.45% to $26.15 on Wednesday after the newborn medical device maker missed Wall Street's fourth-quarter earnings expectations and 2019 guidance. "Record revenue during the fourth quarter 2018 was driven by strong demand across multiple product and market segments.